AstraZeneca signs USD 40 million AI deal. Citi targets AstraZeneca stock at GBp 18,600
Published on 10/19/2026 at 09:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal and upcoming reporting dates
- AstraZeneca entered an insitro collaboration on October 15, 2026 with USD 40 million upfront.
- Citi raised its target to GBp 18,600 from GBp 17,800 on October 6, 2026.
- AstraZeneca stock trades at EUR 146.98 at 9:13 a.m. CEST at Lang & Schwarz on October 19, 2026.
- The company has scheduled ESMO management talks for October 26, 2026.
- AstraZeneca will publish its nine-month and third-quarter results on October 30, 2026.
AstraZeneca (ISIN GB0009895292) was trading at EUR 146.98 at Lang & Schwarz at 9:13 a.m. CEST on October 19, 2026. The company had announced a strategic insitro collaboration on October 15, 2026, including USD 40 million upfront and up to USD 1.46 billion in potential milestones, according to AstraZeneca.
The deal targets two diseases
The agreement covers metabolic dysfunction-associated steatohepatitis and cardiomyopathies. insitro will use its Virtual Human platform to identify disease biology and advance AstraZeneca-nominated targets from discovery to development candidate.
AstraZeneca will hold exclusive worldwide rights to selected programs and will lead clinical development and regulatory work. The financial structure makes the upfront payment small relative to the milestone pool, but the larger payments depend on development and commercial progress.
What does Citi expect from AstraZeneca?
Citi raised its AstraZeneca target to GBp 18,600 from GBp 17,800 and kept a Buy rating on October 6, 2026, according to FMP. The note cited higher peak-sales forecasts for tozorakimab and SERENA-6, while AVANZAR remains an important clinical milestone.
RBC maintained an Outperform rating and a GBp 14,500 target on October 15, 2026. It forecast third-quarter revenue of USD 16.3 billion against USD 16.0 billion consensus and core earnings per share of USD 2.61 against USD 2.59 consensus, according to Proactive.
Two dates shape the next update
AstraZeneca's investor calendar lists an ESMO Meet the Management event for October 26, 2026, followed by its nine-month and third-quarter results on October 30, 2026, on the company's investor-relations page.
Stock trades before the events
The euro quotation places the stock ahead of those scheduled updates while the insitro agreement adds a quantified research investment to the pipeline narrative. The collaboration is still at the discovery stage, so the milestone value is conditional rather than booked revenue.
AstraZeneca was trading at EUR 146.98 at Lang & Schwarz on October 19, 2026 at 9:13 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of AstraZeneca stock.
AstraZeneca stock key data
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Ticker: AZN
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of October 19, 2026, 9:13 a.m. CEST): EUR 146.98
- Sector / Industry: Health care / biopharmaceuticals
- Index membership: FTSE 100
Market context: Market report FTSE 100.
